Discussion
A stem cell therapy conditionally approved in South Korea for treating amyotrophic lateral sclerosis (ALS) will remain available in the Asian nation despite failing to meet the main goal of a late-stage clinical trial that sought to confirm its effectiveness. Developer Corestemchemon announced that Neuronata-R (lenzumestrocel) will…